AstraZeneca Mulls Appeal After Australian Federal Court Rules Crestor Patents Invalid
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca mulls an appeal of an Australian Federal Court judge’s ruling on Crestor patents as the anti-cholesterol drug faces a patent cliff worldwide.